Health Care · Surgical & Medical Instruments & Apparatus · Nasdaq · CIK 1464521 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $25.04Day −2.15%Mkt cap $2.2BOff 52W high −39.3%Vol (1Y) 76.0%
Daily closing price, split-adjusted to the current basis; 0.9y shown of 234 bars on file. Sampled to 234 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest6.8% of sh out |
| Days to cover4.2d |
| 13F net flow (QoQ)+8.00% |
| Top-10 13F concentration65.5% |
| Next report (est.)2026-09-17 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$191.4M |
| Earnings (TTM)-$111.8M |
| Net margin−66.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−14.1% |
Total return through 2026-07-29 · series begins 2025-08-08. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)76.0% |
| Ann. volatility (3Y)76.0% |
| Sharpe (1Y)0.19 |
| Sharpe (3Y)0.19 |
| Max drawdown (1Y)−48.7% |
| Max drawdown (3Y)−48.7% |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 12.0M | $292M | 13.97% | +103.3% |
| Bain Capital Life Sciences Investors, LLC | 10.4M | $254M | 12.18% | −16.1% |
| FMR LLC | 5.4M | $131M | 6.29% | +30.9% |
| BAMCO INC /NY/ | 3.8M | $93M | 4.46% | +66.1% |
| JANUS HENDERSON GROUP PLC | 2.2M | $53M | 2.54% | +152.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.0M | $50M | 2.39% | new |
| Invesco Ltd. | 1.9M | $47M | 2.23% | +231.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.9M | $46M | 2.21% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | −$0.32 | — | $52.6M | +41.3% |
| 2025-12-31 | 2026-03-18 | — | — | $49.1M | — |
| 2025-09-30 | 2025-11-12 | −$1.04 | — | $46.3M | +40.5% |
| 2025-06-30 | 2025-09-10 | −$1.46 | — | $43.4M | +39.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-09-17 is ESTIMATED from filing cadence (median gap 63d) — not company-confirmed.
US 92% · Non Us 8%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
